HIV positivity and anal cancer outcomes

A single-center experience

Nicole Wieghard, Kyle D. Hart, Katherine Kelley, Kim Lu, Daniel Herzig, Timur Mitin, Charles Thomas, Vassiliki Tsikitis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Anal cancer remains common among human immunodeficiency virus (HIV) patients. Chemoradiation has had mixed results. We evaluated outcome differences by HIV status. Methods: We retrospectively analyzed 14 HIV+ and 72 HIV- anal cancer patients (2000 to 2013). Outcomes included chemoradiation tolerance, recurrence, and survival. Results: HIV+ patients were more often male (100% vs 38%, P <.001) but diagnosed at similar stages (P = .49). They were less likely to receive traditional chemotherapy (36% vs 86%, P <.001). Recurrence (P = .55) and survival time (P = .48) were similar across groups. HIV+ patients had similar colostomy-free survival (P = .053). Receipt of 5-fluorouracil/mitomycin C (MMC) chemotherapy predicted recurrence-free and overall survival (Hazard ratios .278, .32). HIV status did not worsen recurrence (P = .71) or survival (P = .57). Conclusions: HIV+ patients received more non-MMC-based chemoradiation but had equivalent colostomy-free, recurrence, and overall survival. Use of 5-fluorouracil/MMC chemotherapy increased after 2008.

Original languageEnglish (US)
JournalAmerican Journal of Surgery
DOIs
StateAccepted/In press - Oct 30 2015

Fingerprint

Anus Neoplasms
HIV
Survival
Recurrence
Colostomy
Mitomycin
Drug Therapy
Fluorouracil

Keywords

  • Anal squamous cell carcinoma
  • HIV
  • Outcomes

ASJC Scopus subject areas

  • Surgery

Cite this

HIV positivity and anal cancer outcomes : A single-center experience. / Wieghard, Nicole; Hart, Kyle D.; Kelley, Katherine; Lu, Kim; Herzig, Daniel; Mitin, Timur; Thomas, Charles; Tsikitis, Vassiliki.

In: American Journal of Surgery, 30.10.2015.

Research output: Contribution to journalArticle

@article{1da6f754618e4039980f01418fee1a1e,
title = "HIV positivity and anal cancer outcomes: A single-center experience",
abstract = "Background: Anal cancer remains common among human immunodeficiency virus (HIV) patients. Chemoradiation has had mixed results. We evaluated outcome differences by HIV status. Methods: We retrospectively analyzed 14 HIV+ and 72 HIV- anal cancer patients (2000 to 2013). Outcomes included chemoradiation tolerance, recurrence, and survival. Results: HIV+ patients were more often male (100{\%} vs 38{\%}, P <.001) but diagnosed at similar stages (P = .49). They were less likely to receive traditional chemotherapy (36{\%} vs 86{\%}, P <.001). Recurrence (P = .55) and survival time (P = .48) were similar across groups. HIV+ patients had similar colostomy-free survival (P = .053). Receipt of 5-fluorouracil/mitomycin C (MMC) chemotherapy predicted recurrence-free and overall survival (Hazard ratios .278, .32). HIV status did not worsen recurrence (P = .71) or survival (P = .57). Conclusions: HIV+ patients received more non-MMC-based chemoradiation but had equivalent colostomy-free, recurrence, and overall survival. Use of 5-fluorouracil/MMC chemotherapy increased after 2008.",
keywords = "Anal squamous cell carcinoma, HIV, Outcomes",
author = "Nicole Wieghard and Hart, {Kyle D.} and Katherine Kelley and Kim Lu and Daniel Herzig and Timur Mitin and Charles Thomas and Vassiliki Tsikitis",
year = "2015",
month = "10",
day = "30",
doi = "10.1016/j.amjsurg.2016.01.009",
language = "English (US)",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - HIV positivity and anal cancer outcomes

T2 - A single-center experience

AU - Wieghard, Nicole

AU - Hart, Kyle D.

AU - Kelley, Katherine

AU - Lu, Kim

AU - Herzig, Daniel

AU - Mitin, Timur

AU - Thomas, Charles

AU - Tsikitis, Vassiliki

PY - 2015/10/30

Y1 - 2015/10/30

N2 - Background: Anal cancer remains common among human immunodeficiency virus (HIV) patients. Chemoradiation has had mixed results. We evaluated outcome differences by HIV status. Methods: We retrospectively analyzed 14 HIV+ and 72 HIV- anal cancer patients (2000 to 2013). Outcomes included chemoradiation tolerance, recurrence, and survival. Results: HIV+ patients were more often male (100% vs 38%, P <.001) but diagnosed at similar stages (P = .49). They were less likely to receive traditional chemotherapy (36% vs 86%, P <.001). Recurrence (P = .55) and survival time (P = .48) were similar across groups. HIV+ patients had similar colostomy-free survival (P = .053). Receipt of 5-fluorouracil/mitomycin C (MMC) chemotherapy predicted recurrence-free and overall survival (Hazard ratios .278, .32). HIV status did not worsen recurrence (P = .71) or survival (P = .57). Conclusions: HIV+ patients received more non-MMC-based chemoradiation but had equivalent colostomy-free, recurrence, and overall survival. Use of 5-fluorouracil/MMC chemotherapy increased after 2008.

AB - Background: Anal cancer remains common among human immunodeficiency virus (HIV) patients. Chemoradiation has had mixed results. We evaluated outcome differences by HIV status. Methods: We retrospectively analyzed 14 HIV+ and 72 HIV- anal cancer patients (2000 to 2013). Outcomes included chemoradiation tolerance, recurrence, and survival. Results: HIV+ patients were more often male (100% vs 38%, P <.001) but diagnosed at similar stages (P = .49). They were less likely to receive traditional chemotherapy (36% vs 86%, P <.001). Recurrence (P = .55) and survival time (P = .48) were similar across groups. HIV+ patients had similar colostomy-free survival (P = .053). Receipt of 5-fluorouracil/mitomycin C (MMC) chemotherapy predicted recurrence-free and overall survival (Hazard ratios .278, .32). HIV status did not worsen recurrence (P = .71) or survival (P = .57). Conclusions: HIV+ patients received more non-MMC-based chemoradiation but had equivalent colostomy-free, recurrence, and overall survival. Use of 5-fluorouracil/MMC chemotherapy increased after 2008.

KW - Anal squamous cell carcinoma

KW - HIV

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84960539051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960539051&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2016.01.009

DO - 10.1016/j.amjsurg.2016.01.009

M3 - Article

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

ER -